Xerostomia one of the Sjögren’s Syndrome Symptoms PDF Print E-mail
Wednesday, 09 June 2010 09:25
“The American Health Institute spent $8 million for a research diagnosis of Sjögren syndrome in several countries as an important disease with high impact on society,” he told The Capital Dr. Ricardo Bazet, ophthalmologist, director of Rosario Self-Help Association for Sjögren syndrome.

One of its main characteristics is the difficulty of arriving at a diagnosis by the multiplicity of symptoms that occurs. This makes the number of fuzzy diagnoses that prevent proper treatment of the disease. “Patients with borderline diagnoses are offered the opportunity to be studies in the German Hospital in Buenos Aires, but not treatment, which should continue in the city of origin,” says Bazet. “The symptoms are not all together,” says the doctor. May occur in different organs by which each specialist is usually just look what it is and not the whole problem. “

Patients who join the study was carried out laboratory tests with blood collection, study eye, Schirmer test, BUT and ocular staining test (fluorescein and lissamine), total and parotid saliva, rheumatologic clinical examination and biopsy of the salivary gland lower. The results of the studies will travel to the U.S. where will supervise each case and classify the data. Finally, the patient returns to information processing will continue with regular doctor.

“The doctors evaluate patients who travel to Buenos Aires for the test. We think it will be two per month, “says the director of the association Rosario, who acknowledges the existence of many patients with misdiagnoses. “The fact that each case is evaluated by the best band in the world Sjögren study determined to be classified the extent of disease (mild, moderate or severe) and that treatment is appropriate to the disease,” adds Bazet.

Treatment should be supervised by a rheumatologist who Bazet as recommended, “must work near an ophthalmologist, pathologist, biochemist and a dermatologist and gynecologist. It seeks to relieve symptoms for a better quality of life, ranging from how to eat, what glasses to use, how to bathe and hydrate the skin, among other guidelines. “

Sjogren’s is an autoimmune disease that causes widespread disruption of the functioning of all the glands of external secretion. The sensation of dry mouth with dry eye are one of the most common. This occurs by decreasing the amount of saliva (hiposalia) or total lack thereof (xerostomia). In most cases occur in this way and a few percent is associated with other autoimmune diseases such as lupus, Scleroderma and psoriasis.

Source: University Five

 
More articles :

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...

» Italians Explain Low Sex Drive In Female Scleroderma Patients

In a world first, Italian rheumatologists have discovered why women living with Systemic Sclerosis often suffer from a low sex drive. The study of 22 women with systemic sclerosis found the disease resulted in a lack of blood flow around the...

» Scleroderma May Be Initated By Cancer

has reported that researchers at have discovered that some cases of are likely to have been initiated by Cancer.  In a landmark paper published in Science, researchers focusing on a select group of patients with both Scleroderma and Cancer,...

» Pain Common in Systemic Sclerosis

Pain is common and can be severe in patients with systemic sclerosis, a cross-sectional analysis found.Among patients enrolled in the multicenter Canadian Scleroderma Research Group Registry, 83% experienced pain, more than one-third of them...

» Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology...

» No Exercise Benefit with Bosentan in Systemic Sclerosis

Treatment with the endothelin receptor antagonist bosentan () failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found. After one year of treatment, there was a nonsignificant mean change in the six-minute...